Toward a Single-Dose Cure for Buruli Ulcer

Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00727-20. doi: 10.1128/AAC.00727-20. Print 2020 Aug 20.

Abstract

A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.

Keywords: Mycobacterium ulcerans; Q203; Telacebec; bedaquiline; bioenergetics; cytochrome bcc-aa3; oxidative phosphorylation; terminal oxidase; tuberculosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Buruli Ulcer* / drug therapy
  • Disease Models, Animal
  • Mice
  • Mycobacterium ulcerans*
  • Tuberculosis*